Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neugranin vs pegfilgrastim in breast cancer patients receiving myelosuppressive chemotherapy
2010-019001-42Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of balugrastim in neutropenia, febrile neutropenia (FN) and Infection (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Efficacy of Neugranin vs pegfilgrastim on neutropenia outcomes, Incidence of febrile neutropenia and 1 more. Started Apr 2010; status: completed.
02
Drugs
balugrastim
03
Conditions
neutropeniafebrile neutropenia (FN)Infection
Beyond the preview
Go deeper on 2010-019001-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019001-42.